Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
复制标题
DOI：
10.1038/s41408-021-00534-z
复制
发表时间：
2021-08-10
影响因子：
12.8
通讯作者：
Mohty M
中科院分区：
文献类型：
--
作者：
Malard F;Gaugler B;Gozlan J;Bouquet L;Fofana D;Siblany L;Eshagh D;Adotevi O;Laheurte C;Ricard L;Dulery R;Stocker N;van de Wyngaert Z;Genthon A;Banet A;Memoli M;Ikhlef S;Sestilli S;Vekhof A;Brissot E;Marjanovic Z;Chantran Y;Cuervo N;Ballot E;Morand-Joubert L;Mohty M
本研究评价了BNT 162 b2疫苗在血液系统恶性肿瘤患者中的安全性和免疫原性。阻断刺突与固定化ACE-2（NAb）结合的抗体与抗刺突（S）IgG d42滴度相关（斯皮尔曼r = 0.865，p < 0.0001），抗S IgG d42水平≥3100 UA/mL预示NAb ≥ 30%，即NAb的阳性临界值（p < 0.0001）。在两次BNT 162 b2接种后，只有47%的患者达到抗S IgG d42水平≥3100 UA/mL，而健康对照组为87%。在多变量分析中，男性患者、在疫苗接种前的最后12个月内使用B细胞靶向治疗以及CD 19 + B细胞水平<120/uL与第二次BNT 162 b2接种后达到保护性抗S IgG水平的概率显著降低相关。最后，使用IFN-γ ELISPOT测定，我们发现针对S蛋白的T细胞应答显著增加，在第二次BNT 162 b2接种后，53%的患者具有抗S IgG阳性ELISPOT。抗S ELISPOT应答与IgG d42水平之间存在相关性（斯皮尔曼r = 0.3026，p = 0.012）。这些发现表明，接种两种BNT 162 b2接种物可显著增加血液恶性肿瘤患者的体液和细胞反应，但只有大约一半的患者可能获得有效的免疫保护，以对抗COVID-19。
This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865, p < 0.0001), and an anti-S IgG d42 level ≥3100 UA/mL was predictive of NAb ≥ 30%, the positivity cutoff for NAb (p < 0.0001). Only 47% of the patients achieved an anti-S IgG d42 level ≥3100 UA/mL after the two BNT162b2 inocula, compared to 87% of healthy controls. In multivariable analysis, male patients, use of B-cell targeting treatment within the last 12 months prior to vaccination, and CD19+ B-cell level <120/uL, were associated with a significantly decreased probability of achieving a protective anti-S IgG level after the second BNT162b2 inoculum. Finally, using the IFN-γ ELISPOT assay, we found a significant increase in T-cell response against the S protein, with 53% of patients having an anti-S IgG-positive ELISPOT after the second BNT162b2 inoculum. There was a correlation between the anti-S ELISPOT response and IgG d42 level (Spearman r = 0.3026, p = 0.012). These findings suggest that vaccination with two BNT162b2 inocula translates into a significant increase in humoral and cellular response in patients with hematological malignancies, but only around half of the patients can likely achieve effective immune protection against COVID-19.
登录
查看更多内容
影响因子：
82.9
作者：
Lucas C;Klein J;Sundaram ME;Liu F;Wong P;Silva J;Mao T;Oh JE;Mohanty S;Huang J;Tokuyama M;Lu P;Venkataraman A;Park A;Israelow B;Vogels CBF;Muenker MC;Chang CH;Casanovas-Massana A;Moore AJ;Zell J;Fournier JB;Yale IMPACT Research Team;Wyllie AL;Campbell M;Lee AI;Chun HJ;Grubaugh ND;Schulz WL;Farhadian S;Dela Cruz C;Ring AM;Shaw AC;Wisnewski AV;Yildirim I;Ko AI;Omer SB;Iwasaki A
通讯作者：
Iwasaki A
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
五个可获得五种可获得SARS-COV-2抗体并鉴定具有高中和滴度的个体的抗体的比较性能。
影响因子：
9.4
作者：
Patel EU;Bloch EM;Clarke W;Hsieh YH;Boon D;Eby Y;Fernandez RE;Baker OR;Keruly M;Kirby CS;Klock E;Littlefield K;Miller J;Schmidt HA;Sullivan P;Piwowar-Manning E;Shrestha R;Redd AD;Rothman RE;Sullivan D;Shoham S;Casadevall A;Quinn TC;Pekosz A;Tobian AAR;Laeyendecker O
通讯作者：
Laeyendecker O
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group